Philippe Pultar

580 total citations
17 papers, 413 citations indexed

About

Philippe Pultar is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Philippe Pultar has authored 17 papers receiving a total of 413 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Oncology. Recurrent topics in Philippe Pultar's work include Lung Cancer Treatments and Mutations (4 papers), Neuroendocrine Tumor Research Advances (3 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). Philippe Pultar is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Neuroendocrine Tumor Research Advances (3 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). Philippe Pultar collaborates with scholars based in United States, Switzerland and Spain. Philippe Pultar's co-authors include Enriqueta Felip, Mikhail Akimov, James Chih‐Hsin Yang, Dae Ho Lee, Sabine Glaser, Wu‐Chou Su, Li Zhang, Daniel S.W. Tan, Dong‐Wan Kim and Myung‐Ju Ahn and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Philippe Pultar

17 papers receiving 405 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Philippe Pultar United States 8 235 193 175 65 65 17 413
L. Hart United States 11 183 0.8× 254 1.3× 220 1.3× 33 0.5× 66 1.0× 25 518
Xin‐Gan Qin China 11 114 0.5× 96 0.5× 139 0.8× 84 1.3× 69 1.1× 25 316
Brian Simmons United States 12 204 0.9× 209 1.1× 124 0.7× 27 0.4× 74 1.1× 34 402
C. Ligorio Italy 6 404 1.7× 426 2.2× 230 1.3× 46 0.7× 108 1.7× 8 614
Anna Świeboda-Sadlej Poland 8 153 0.7× 248 1.3× 145 0.8× 29 0.4× 61 0.9× 16 385
Chun‐Chieh Wu Taiwan 12 171 0.7× 200 1.0× 187 1.1× 77 1.2× 87 1.3× 32 466
Chan Xiang China 12 140 0.6× 95 0.5× 167 1.0× 47 0.7× 124 1.9× 32 378
Soo Chin Canada 6 189 0.8× 256 1.3× 185 1.1× 170 2.6× 199 3.1× 10 536
Masato Komoda Japan 11 91 0.4× 186 1.0× 183 1.0× 38 0.6× 54 0.8× 32 408
Alessandra Cocomazzi Italy 11 72 0.3× 106 0.5× 116 0.7× 73 1.1× 48 0.7× 17 363

Countries citing papers authored by Philippe Pultar

Since Specialization
Citations

This map shows the geographic impact of Philippe Pultar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Pultar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Pultar more than expected).

Fields of papers citing papers by Philippe Pultar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Pultar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Pultar. The network helps show where Philippe Pultar may publish in the future.

Co-authorship network of co-authors of Philippe Pultar

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Pultar. A scholar is included among the top collaborators of Philippe Pultar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Pultar. Philippe Pultar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Lim, Kian‐Huat, Kristen Spencer, Rachael A. Safyan, et al.. (2024). Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b/2 study (RAMP 205).. Journal of Clinical Oncology. 42(16_suppl). 4140–4140. 9 indexed citations
2.
Meric‐Bernstam, Funda, Hirva Mamdani, Cheng Zheng, et al.. (2022). Abstract CT029: Safety and clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 trial in subjects with recurrent or advanced uterine serous carcinoma (USC). Cancer Research. 82(12_Supplement). CT029–CT029. 13 indexed citations
3.
4.
5.
Avutu, Viswatej, Emily K. Slotkin, Sant P. Chawla, et al.. (2022). A phase 1/2 dose-escalation and dose-expansion study of ZN-c3 in combination with gemcitabine in adult and pediatric subjects with relapsed or refractory osteosarcoma.. Journal of Clinical Oncology. 40(16_suppl). TPS11584–TPS11584. 3 indexed citations
6.
7.
Samson, Susan L., Feng Gu, Ulla Feldt‐Rasmussen, et al.. (2021). Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study. Pituitary. 24(6). 887–903. 42 indexed citations
8.
Chalasani, Pavani, Anthony W. Tolcher, Funda Meric‐Bernstam, et al.. (2021). 526P Pharmacodynamic evidence for WEE1 target engagement in surrogate and tumor tissues from a phase I study of the WEE1 inhibitor ZN-c3. Annals of Oncology. 32. S593–S593. 1 indexed citations
9.
Tolcher, Anthony W., Hirva Mamdani, Pavani Chalasani, et al.. (2021). Abstract CT016: Clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 dose-escalation trial in patients with advanced solid tumors. Cancer Research. 81(13_Supplement). CT016–CT016. 20 indexed citations
10.
11.
12.
Kim, Dong‐Wan, Daniel Shao-Weng Tan, Santiago Ponce Aix, et al.. (2018). Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 36(15_suppl). 9094–9094. 13 indexed citations
13.
Tan, Daniel Shao-Weng, Dae Ho Lee, Ross A. Soo, et al.. (2017). P3.02b-117 Phase Ib Results from a Study of Capmatinib (INC280) + EGF816 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12(1). S1264–S1265. 6 indexed citations
14.
15.
Riess, Jonathan W., Nupur Bhattacharya, Kim Blenman, et al.. (2014). Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients. Immunopharmacology and Immunotoxicology. 36(2). 182–186. 3 indexed citations
16.
17.
Rowinsky, Eric K., Jonathan D. Schwartz, Naseem J. Zojwalla, et al.. (2011). Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers. Current Drug Targets. 12(14). 2016–2033. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. Hart Breakdown of academic impact, for papers by Xin‐Gan Qin Breakdown of academic impact, for papers by Brian Simmons Breakdown of academic impact, for papers by C. Ligorio Breakdown of academic impact, for papers by Anna Świeboda-Sadlej Breakdown of academic impact, for papers by Chun‐Chieh Wu Breakdown of academic impact, for papers by Chan Xiang Breakdown of academic impact, for papers by Soo Chin Breakdown of academic impact, for papers by Masato Komoda Breakdown of academic impact, for papers by Alessandra Cocomazzi
Rankless by CCL
2026